SPY757.04−0.36%QQQ685.21−0.75%BTC/USD73,342.97−0.79%DIA525.02+0.11%GLD362.14−0.83%TLT80.99+0.09%

Corbus Pharmaceuticals Holdings Inc

CRBPNASDAQ

Trade with Public

$4.00

0.071.78%

Last update: Nov 12, 4:33 AM

Overview News Charts Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

Earnings: Q3 2026 Earnings were released on Mon Nov 9th, after the market close

Corbus Pharmaceuticals (CRBP) Stock Price Target 2026

See analyst price targets, ratings and recent upgrades and downgrades for Corbus Pharmaceuticals (CRBP) stock.

Analyst Consensus — 10 Analysts

10Buy

# Analysts10

Latest Upgrades and Downgrades for Corbus Pharmaceuticals Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
—	RBC Capital	Brian Abrahams	PT Cut	Outperform	$36→$33
—	Wedbush	Robert Driscoll	PT Cut	Outperform	$30→$27
—	HC Wainwright & Co.	Andres Y. Maldonado	Maintained	Buy	$35
—	Oppenheimer	Jeff Jones	PT Cut	Outperform	$52→$48
—	HC Wainwright & Co.	Andres Y. Maldonado	PT Cut	Buy	$40→$35
—	Mizuho	Graig Suvannavejh	PT Cut	Outperform	$44→$34
—	Oppenheimer	Jeff Jones	PT Cut	Outperform	$54→$52
—	Wedbush	Robert Driscoll	PT Cut	Outperform	$38→$30
—	HC Wainwright & Co.	Andres Y. Maldonado	Maintained	Buy	$40
—	Mizuho	Graig Suvannavejh	PT Raise	Outperform	$40→$44
—	Jefferies	Maury Raycroft	PT Cut	Buy	$36→$33
—	Oppenheimer	Jeff Jones	PT Cut	Outperform	$57→$54
—	Guggenheim	Paul Jeng	Maintained	Buy	$45
—	Guggenheim	Paul Jeng	Initiate	Buy	$45
—	Oppenheimer	Jeff Jones	PT Raise	Outperform	$53→$57
—	RBC Capital	Brian Abrahams	PT Cut	Outperform	$55→$53
—	Wedbush	Robert Driscoll	PT Raise	Outperform	$31→$38
—	HC Wainwright & Co.	Andres Y. Maldonado	Maintained	Buy	$40
—	HC Wainwright & Co.	Andres Y. Maldonado	Maintained	Buy	$40
—	Oppenheimer	Jeff Jones	PT Cut	Outperform	$56→$53

Corbus Pharmaceuticals Holdings Inc

Corbus Pharmaceuticals (CRBP) Stock Price Target 2026

Latest Upgrades and Downgrades for Corbus Pharmaceuticals Stock

Corbus Pharmaceuticals (CRBP) Stock Price Target 2026

Latest Upgrades and Downgrades for Corbus Pharmaceuticals Stock

Analyst Ratings News

PRO
RBC Capital Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $33

PRO
Wedbush Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $27

PRO
HC Wainwright & Co. Reiterates Buy on Corbus Pharmaceuticals, Maintains $35 Price Target

PRO
Oppenheimer Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $48

PRO
HC Wainwright & Co. Maintains Buy on Corbus Pharmaceuticals, Lowers Price Target to $35

PRO
Mizuho Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $34

People Also Watch

People Also Watch

Analyst Ratings News

PRO
RBC Capital Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $33

PRO
Wedbush Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $27

PRO
HC Wainwright & Co. Reiterates Buy on Corbus Pharmaceuticals, Maintains $35 Price Target

PRO
Oppenheimer Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $48

PRO
HC Wainwright & Co. Maintains Buy on Corbus Pharmaceuticals, Lowers Price Target to $35

PRO
Mizuho Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $34

Corbus Pharmaceuticals Holdings Inc

Corbus Pharmaceuticals (CRBP) Stock Price Target 2026

Latest Upgrades and Downgrades for Corbus Pharmaceuticals Stock

Corbus Pharmaceuticals (CRBP) Stock Price Target 2026

Latest Upgrades and Downgrades for Corbus Pharmaceuticals Stock

Analyst Ratings News

PRORBC Capital Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $33

PROWedbush Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $27

PROHC Wainwright & Co. Reiterates Buy on Corbus Pharmaceuticals, Maintains $35 Price Target

PROOppenheimer Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $48

PROHC Wainwright & Co. Maintains Buy on Corbus Pharmaceuticals, Lowers Price Target to $35

PROMizuho Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $34

People Also Watch

People Also Watch

Analyst Ratings News

PRORBC Capital Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $33

PROWedbush Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $27

PROHC Wainwright & Co. Reiterates Buy on Corbus Pharmaceuticals, Maintains $35 Price Target

PROOppenheimer Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $48

PROHC Wainwright & Co. Maintains Buy on Corbus Pharmaceuticals, Lowers Price Target to $35

PROMizuho Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $34

PRO
RBC Capital Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $33

PRO
Wedbush Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $27

PRO
HC Wainwright & Co. Reiterates Buy on Corbus Pharmaceuticals, Maintains $35 Price Target

PRO
Oppenheimer Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $48

PRO
HC Wainwright & Co. Maintains Buy on Corbus Pharmaceuticals, Lowers Price Target to $35

PRO
Mizuho Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $34

PRO
RBC Capital Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $33

PRO
Wedbush Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $27

PRO
HC Wainwright & Co. Reiterates Buy on Corbus Pharmaceuticals, Maintains $35 Price Target

PRO
Oppenheimer Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $48

PRO
HC Wainwright & Co. Maintains Buy on Corbus Pharmaceuticals, Lowers Price Target to $35

PRO
Mizuho Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $34